GlassScriptPhysician profile
Michelle Gavala
NPI 1881058436
$2,086.90
in general payments reported to CMS, 2019-2025
23 companies · $379 in 2025
The $379 reported for 2025 was more than what 80% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2022: $711 · 2023: $458 · 2024: $260 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.61 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $224.40 | 2022-2025 | |
| Abbvie INC. | $202.20 | 2022-2024 | |
| Millicent US INC | $199.02 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Sumitomo Pharma America, INC. | $165.98 | 2023 | Myfembree |
| Agile Therapeutics, INC. | $154.96 | 2021-2024 | Twirla |
| Exeltis, USA INC. | $135.49 | 2021-2025 | Slynd |
| Evofem Biosciences, INC. | $129.48 | 2021-2025 | Phexxi, Solosec, Phexx |
| Therapeuticsmd, INC. | $126.04 | 2021-2022 | |
| Myovant Sciences INC. | $117.65 | 2021-2022 | |
| Astellas Pharma US INC | $83.87 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $79.11 | 2022-2025 | |
| Baxter Healthcare | $78.28 | 2024 | Perclot |
| Daiichi Sankyo INC. | $76.91 | 2021-2023 | Injectafer |
| Organon LLC | $58.22 | 2024-2025 | Jada System, Nexplanon |
| Hologic Sales and Service, LLC | $41.59 | 2025 | Aptima |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $41.50 | 2022 | |
| Avion Pharmaceuticals | $38.70 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $29.93 | 2021 | |
| Mylan Pharmaceuticals INC. | $28.92 | 2022 | |
| Pfizer INC. | $28.79 | 2022-2023 | |
| Urovant Sciences INC | $16.13 | 2022 | |
| Lupin INC. | $15.00 | 2021 | |
| Sage Therapeutics, LLC | $14.73 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Gavala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.